NY-THE-LIVEKINDLY-CO.
11.3.2020 11:02:14 CET | Business Wire | Press release
The LIVEKINDLY co. is leading a movement to build a sustainable future, today, fueled by a $200-million founders’ funding round led by founders, entrepreneurs, and global leaders. Establishing a collective of heritage and start-up brands, the company is on track to become one of the world’s largest plant-based food companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200311005184/en/
Brands under the LIVEKINDLY co. portfolio offer consumers non-GMO, plant-based chicken alternatives and include: The Fry Family Food Co. and LikeMeat, as well as the fastest-growing plant-based digital media platform, LIVEKINDLY Media –from which the new company's name derives and means embracing a sustainable and compassionate lifestyle. With these investments and an equity stake in PURIS Holding , a vertically integrated player of non-GMO, plant-based ingredients, the LIVEKINDLY co. is the only company in the plant-based food sector to own and operate the entire value chain of production.
The LIVEKINDLY co. is committed to transforming the global food system by partnering with forward-looking poultry production companies seeking to embrace and contribute to plant-based options. Products offer consumers recognizable natural ingredients made with environmentally friendly meat alternatives that mimic the taste and texture of chicken.
Plant-based food products are becoming increasingly popular as consumer demand for cleaner, more sustainable options grow, and production technologies improve to significantly enhance taste and texture. The plant-based protein market could reach 9% of the estimated $2.7 trillion global meat market by 20401 , positioning the LIVEKINDLY co. for strong future growth.
Leading the LIVEKINDLY co. is a global team of industry executives including Kees Kruythoff, Chairman & CEO (formerly President Unilever North America and Global Home Care Division); Roger Lienhard, Board of Directors and Founder (founder of Blue Horizon Corporation); and Jodi Monelle , CEO and Founder LIVEKINDLY Media. The leadership team includes veterans of the food industry: Mick Van Ettinger , Chief Marketing Officer (formerly of Unilever), and Aldo Uva , COO and Chief R&D Officer (formerly of Nestle, Firmenich, and Ferrero).
“Unlike any other company in this space, the LIVEKINDLY co. is creating a movement that will drive impact at scale and at speed,” said Kruythoff. “We are starting with one of the world’s most consumed meats–chicken-by providing outstanding, tasty, plant-based foods that are more sustainable and environmentally friendly. We’re also partnering with incumbent poultry companies including PHW in Europe and RCL Foods in South Africa, who are committed to embracing plant-based options.”
“The LIVEKINDLY co.'s approach offers a path forward for transforming the global food industry. Our team has built a new formula for success by bringing innovation, experience, resources, and scale throughout the plant-based chicken value chain,” said Lienhard. “It started with bringing together like-minded founders who share a vision for smarter, sustainable living, and allows the food industry to better align around the evolving values of consumers who are focused on climate change, animal welfare, and human health.”
The founders’ round of funding will be used for further acquisitions, scaling the current plant-based food portfolio of brands and investments to rapidly increase the plant-based food industry capacity.
ABOUT THE LIVEKINDLY CO.
The LIVEKINDLY co. is a collective of plant-based heritage and start-up brands including: The Fry Family Food Co., LikeMeat, and LIVEKINDLY Media.
Committed to transforming our global food system and the only company in the plant-based food sector to own and operate the entire value chain of production, the LIVEKINDLY co. has established strategic partnerships with seed growers, producers, distributors, and has invested in infrastructure to transform traditional meat production facilities to plant-based products.
The LIVEKINDLY co. and its portfolio of brands are creating delicious plant-based food without the need for animals or the depletion of natural resources. We’re bringing kindness where it belongs: to your plate.
ABOUT BLUE HORIZON CORPORATION
Blue Horizon was founded in 2015 with the vision that profit-oriented strategies and the common good can be united. Blue Horizon is a global-mission-driven private sector investment firm focused on scalable ventures that accelerate that global transition towards sustainable food and agriculture.
To learn more, visit our website .
1 https://www.jefferies.com/CMSFiles/Jefferies.com/Files/Insights/The_Great_Protein_Shakeup.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005184/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom